BioNTech (UK) Performance
| 0A3M Stock | 116.10 4.01 3.58% |
On a scale of 0 to 100, BioNTech holds a performance score of 10. The firm shows a Beta (market volatility) of 0.84, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioNTech's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNTech is expected to be smaller as well. Please check BioNTech's standard deviation, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to make a quick decision on whether BioNTech's price patterns will revert.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, BioNTech unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | BioNTech price tries to gather positive momentum - Forecast today - 26-09-2024 - Economies.com | 09/26/2024 |
2 | BioNTech Rings the Nasdaq Stock Market Opening Bell - Nasdaq | 11/14/2024 |
3 | BioNTech ADR Earns Relative Strength Rating Upgrade - Investors Business Daily | 11/22/2024 |
BioNTech |
BioNTech Relative Risk vs. Return Landscape
If you would invest 8,743 in BioNTech SE on August 27, 2024 and sell it today you would earn a total of 2,867 from holding BioNTech SE or generate 32.79% return on investment over 90 days. BioNTech SE is generating 0.5052% of daily returns and assumes 3.7655% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than BioNTech, and 90% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioNTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNTech SE, and traders can use it to determine the average amount a BioNTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1342
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 0A3M | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.77 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average BioNTech is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNTech by adding it to a well-diversified portfolio.
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | -0.024 | ||||
| Return On Asset | -0.0124 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 10.41 B | ||||
| Revenue | 3.04 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | (274.5 M) | ||||
| Net Income | 9.43 B | ||||
| Book Value Per Share | 79.73 X | ||||
| Cash Flow From Operations | 889.7 M | ||||
| Earnings Per Share | 52.02 X | ||||
| Retained Earnings | 9.88 B |
About BioNTech Performance
Assessing BioNTech's fundamental ratios provides investors with valuable insights into BioNTech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the BioNTech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
BioNTech is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNTech SE appears to be risky and price may revert if volatility continues | |
| About 62.0% of the company shares are owned by insiders or employees | |
| Latest headline from news.google.com: BioNTech ADR Earns Relative Strength Rating Upgrade - Investors Business Daily |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.